RESUMO
Novel aryl amide analogues of glutamic acid dialkylamide have been synthesized to test for a possible structural analogy between glutamic acid and benzodiazepine CCK antagonists such as compounds 2 and 24 (lorglumide and MK-329, respectively). In support of the structural model, certain of these hybrid compounds are more potent in pancreas CCK radioligand binding assays than corresponding lorglumide-type reference compounds. Modifications previously found in the benzodiazepine antagonists to result in brain CCK/gastrin receptor selectivity were also incorporated to produce an aryl urea series of glutamic acid analogues. None of these compounds were brain CCK/gastrin selective; however, one was potent and selective in the pancreas binding assay. The model appears to be most useful in the design of selective ligands for the pancreas type CCK receptor.
Assuntos
Colecistocinina/análogos & derivados , Receptores da Colecistocinina/metabolismo , Animais , Encéfalo/metabolismo , Fenômenos Químicos , Química , Físico-Química , Colecistocinina/metabolismo , Gráficos por Computador , Glutamatos , Cobaias , Ligantes , Modelos Moleculares , Conformação Molecular , Pâncreas/metabolismo , Ratos , Relação Estrutura-AtividadeRESUMO
Tifluadom, a kappa-opioid agonist and cholecystokinin-A (CCK-A) receptor antagonist, was utilized as a model to prepare a series of 2-(aminomethyl)- and 3-(aminomethyl)-1,4-benzodiazepines. These compounds were tested in vitro as inhibitors of the binding of [125I]CCK to rat pancreas and guinea pig brain receptors. All compounds with IC50's less than 100 microM proved to have greater affinity for the CCK-A receptor, with the most potent analogue, 6e, having an IC50 of 0.16 microM. The benzodiazepines described in this study are simultaneously CCK-A and opioid receptor ligands. The ramification of this dichotomy on current concepts of peptide hormone action are discussed. These results further demonstrate the versatility of the benzodiazepine core structure for designing nonpeptide ligands for peptide receptors and the ability to fine-tune the receptor interactions of these benzodiazepines by appropriate structure modifications.
Assuntos
Benzodiazepinas/farmacologia , Receptores da Colecistocinina/metabolismo , Receptores Opioides/metabolismo , Animais , Benzodiazepinas/síntese química , Encéfalo/metabolismo , Córtex Cerebral/metabolismo , Fenômenos Químicos , Química , Colecistocinina/metabolismo , Di-Hidromorfina/metabolismo , Cobaias , Estrutura Molecular , Naloxona/metabolismo , Pâncreas/metabolismo , Ratos , Receptores Opioides kappa , Sincalida/metabolismoRESUMO
3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described. Developed by reasoned modification of the known anxiolytic benzodiazepines, these compounds provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8. The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compounds. Details of the binding of these agents to CCK-A receptors are examined, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.
Assuntos
Benzodiazepinas/síntese química , Colecistocinina/antagonistas & inibidores , Desenho de Fármacos , Administração Oral , Animais , Benzodiazepinas/metabolismo , Fenômenos Químicos , Química , Camundongos , Receptores da Colecistocinina/metabolismo , Receptores de GABA-A/metabolismo , Relação Estrutura-AtividadeRESUMO
Nineteen tetrapeptides containing statine (Sta) and 4-amino-5-cyclohexyl-3-hydroxypentanoic acid (ACHPA) were prepared. Solubility measurements of these compounds were carried out in H2O and in pH 7.4 phosphate buffer solution, and their partition coefficients were determined in a 1:1 1-octanol/sodium phosphate-citric acid buffer system. The tetrapeptides were tested in vitro for their ability to inhibit porcine, canine, and human plasma renins. Four compounds, 6, 12, 14, and 20, were potent inhibitors against all renins tested (IC50 = 10(-9) M). Compound 12 was administered orally to dogs and substantially inhibited plasma renin activity for up to 5 h. The addition of polar groups to the C-terminus of Sta- and ACHPA-containing tetrapeptides renders them soluble in aqueous milieu and provides a valuable tool with which to examine the role of the renin-angiotensin system in physiological and pathological circumstances.
Assuntos
Oligopeptídeos/síntese química , Renina/antagonistas & inibidores , Aminoácidos/farmacologia , Animais , Cães , Humanos , Oligopeptídeos/farmacologia , Solubilidade , Relação Estrutura-Atividade , SuínosRESUMO
A series of 3-(arylureido)-5-phenyl-1,4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK), are described. Derived by reasoned modification of the CCK-A selective 3-carboxamido-1,4-benzodiazepine, MK-329, this paper chronicles the development of potent, orally effective compounds in which selectivity for the CCK-B receptor subtype was achieved. The principal lead structure that emerged from these studied is L-365,260, a compound which has been submitted for clinical evaluation. Details of the ability to modulate the receptor interactions of these benzodiazepines by appropriate structure modifications are discussed which imply the possibility of further refining the CCK-B receptor affinity and selectivity of this class of compounds.
Assuntos
Benzodiazepinas/síntese química , Benzodiazepinonas/síntese química , Compostos de Fenilureia , Receptores da Colecistocinina/antagonistas & inibidores , Animais , Benzodiazepinas/farmacocinética , Benzodiazepinas/farmacologia , Benzodiazepinonas/química , Benzodiazepinonas/farmacocinética , Benzodiazepinonas/farmacologia , Disponibilidade Biológica , Córtex Cerebral/metabolismo , Devazepida , Cobaias , Estrutura Molecular , Pâncreas/metabolismo , Ratos , Sincalida/metabolismo , Relação Estrutura-AtividadeRESUMO
A new structural class of cyclic hexapeptide oxytocin antagonists derived from Streptomyces silvensis and typified by L-365,209 (cyclo-[L-prolyl1-D-phenylalanyl2-L- isoleucyl3-D-dehydropiperazyl4-L-dehydroperazyl5-D-(N- methyl)phenylalanyl6]) was recently reported. In this paper we further delineate the structure-activity profile for this new class by systematic study of L-365,209 analogs obtained by total synthesis. The optimal combination of cyclic amino acid ring sizes at positions 1, 4, and 5 and the role of the N-alkyl substituent at position 6 was elucidated. The lipophilic amino acids at positions 2 and 3 and the unusual amino acid D-dehydropiperazic acid at position 4 were found to be the most critical residues for obtaining good oxytocin receptor affinity. Analogs containing a basic side chain at the less critical 5- and 6-positions maintained good receptor affinity and also had useful levels of water solubility for intravenous formulation. By combining potency- and solubility-enhancing substitutions, several analogs were identified that have the desired combination of properties in vitro (22, cyclo-[L-prolyl-D-tryptophanyl-L-isoleucyl-D-pipecolyl-L-pipeco lyl-D- histidyl]; 25, cyclo-[L-prolyl-D-2-naphthylalanyl-L-isoleucyl-D-pipecolyl-L -pipecolyl-D- histidyl]; 26, cyclo-[L-prolyl-D-tryptophanyl-L-isoleucyl-D-dehydropiperazyl-L-++ pipecolyl-D-histidyl]; 33, cyclo-[L-prolyl-D-tryptophanyl-L-isoleucyl-D-pipecolyl-L- piperazinylcarboxy-D-(N-methyl)phenylalanyl]; 34, cyclo-[L-prolyl-D-phenylalanyl-L-isoleucyl-D-dehydropiperazyl-L-or nithyl- D-(N-methyl)phenylalanyl]). In general, this class exhibited good selectivity for binding to the oxytocin receptor versus the arginine vasopressin V1a and V2 receptor subtypes, although increased V2 receptor affinity was observed in one case (32, cyclo[L-prolyl-D-2-naphthylalanyl-L-isoleucyl-D-pipecolyl-L- lysyl-D-(N- methyl)phenylalanyl]). Unexpectedly, compound 33 was found to stimulate contractions of the isolated rat uterus via activation of the uterine bradykinin receptor. Compounds 22, 25, 26, 33, and 34 were found to be potent antagonists of oxytocin-stimulated contraction of the rat uterus in vitro and in vivo. Compounds 22 and 25 were additionally characterized as potent antagonists of oxytocin-stimulated uterine contractions in the near-term pregnant rhesus monkey. These studies thus demonstrate the selectivity and efficacy of certain members of this novel class of antagonists and suggest their use as pharmacological tools in further defining the role of oxytocin in both term and preterm labor.
Assuntos
Ocitocina/antagonistas & inibidores , Peptídeos Cíclicos/farmacologia , Sequência de Aminoácidos , Animais , Feminino , Haplorrinos , Técnicas In Vitro , Masculino , Dados de Sequência Molecular , Ocitocina/metabolismo , Peptídeos Cíclicos/química , Ensaio Radioligante , Ratos , Receptores de Angiotensina/metabolismo , Receptores de Ocitocina , Streptomyces/metabolismo , Relação Estrutura-Atividade , Especificidade por SubstratoRESUMO
A series of 3-substituted 5-phenyl-1,4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK), have been synthesized. Designed on the basis of facts regarding CCK, its natural-product antagonist asperlicin (3), and the antianxiety agent diazepam (4), these compounds represent a significant departure from existing CCK antagonists. They also constitute perhaps the first examples of simple, nonpeptidal ligands for a peptide receptor to arise by design rather than by screening. These compounds serve to illuminate the distinction between central and peripheral CCK receptors, as well as to provide orally effective CCK antagonists of potential pharmacological or therapeutic utility. One rationale for their receptor affinity has possible applications in the design of nonpeptidal ligands for other receptors, peptidal as well as nonpeptidal.
Assuntos
Benzodiazepinas/síntese química , Colecistocinina/antagonistas & inibidores , Receptores da Colecistocinina/análise , Animais , Ansiolíticos , Benzodiazepinas/metabolismo , Cobaias , Ligantes/síntese química , Ratos , Receptores de GABA-A/análise , Relação Estrutura-AtividadeAssuntos
Benzodiazepinas/síntese química , Benzodiazepinas/metabolismo , Benzodiazepinonas , Compostos de Fenilureia , Receptores da Colecistocinina/metabolismo , Animais , Benzodiazepinas/farmacologia , Ligação Competitiva , Encéfalo/metabolismo , Gastrinas/metabolismo , Cobaias , Ligantes , Ensaio Radioligante , Ratos , Relação Estrutura-AtividadeAssuntos
Indolquinonas , Indóis/farmacologia , Radiossensibilizantes , Radioterapia/métodos , Sarcoma Experimental/radioterapia , Animais , Relação Dose-Resposta à Radiação , Feminino , Radicais Livres , Metronidazol/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Oxirredução , Radiólise de Impulso , Sarcoma Experimental/patologia , Vitamina K/farmacologiaRESUMO
We describe the design and synthesis of nonpeptidal antagonists of the peptide hormone cholecystokinin. Several of these compounds have high specificity and nanomolar binding affinity and are active after oral administration. To our knowledge, the design of such agents has not previously been accomplished for any peptide hormone. The structural similarities between these synthetic compounds and the anxiolytic 1,4-benzodiazepines are noted, and the potential of this structural feature for future design of ligands for other peptide hormone receptors is discussed.